The small-cap biotech featured in today’s article develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries. As a result of the pandemic, the stock more than doubled from its March 2020 low, but a pullback may now provide investors who missed out on those gains with an attractive entry point. For more, CLICK HERE.
“Powered By The Pandemic”: An Attractive Entry Point For This Small-Cap Biotech?
- by RobH